Markets mapped
● GREEN9/9
full pathway documented
Avg. time-to-access
10.0 mo
submission to listing
Tender / regional-tender
4
IT · ES · PL · SE
High complexity
● AMBER4
UK · DE · FR · IT
Verification required
● RED8
1 market(s) high confidence
Per-market summary
🇬🇧 United Kingdom
FSMP
NHS England / ICBs (Integrated Care Boards)
Borderline substance14 mo
● High12 SKUs
🇩🇪 Germany
FSMP
GKV (Gesetzliche Krankenversicherung) - statutory health insurance funds
Insurer-led12 mo
● Moderate12 SKUs
🇫🇷 France
FSMP
CNAM / Assurance Maladie; CEPS negotiates prices
National list11 mo
● Moderate12 SKUs
🇮🇹 Italy
FSMP
Regional health authorities (ASL / SSN); significant regional variation
Regional tender9 mo
● Moderate12 SKUs
🇪🇸 Spain
FSMP
SNS (Sistema Nacional de Salud); managed via CCAA (17 autonomous communities) with significant autonomy
Regional tender10 mo
● Moderate12 SKUs
🇳🇱 Netherlands
FSMP
Private health insurers (Achmea / VGZ / CZ / Menzis cover ~85%); basic insurance (basisverzekering) covers prescribed FSMPs
Insurer-led8 mo
● Moderate-High12 SKUs
🇧🇪 Belgium
FSMP
NIHDI / RIZIV-INAMI; mutualites administer claims
Reimbursement9 mo
● Low-Moderate12 SKUs
🇵🇱 Poland
FSMP
NFZ (Narodowy Fundusz Zdrowia) - single national payer
Tender7 mo
● Low-Moderate12 SKUs
🇸🇪 Sweden
FSMP
21 regional county councils (regioner) - each region procures independently; no single national payer for FSMPs
Regional tender10 mo
● Moderate12 SKUs
Detailed drill-down
Regulatory classification
FSMP - listed as Borderline Substance
Primary approval / listing body
ACBS (Advisory Committee on Borderline Substances) - independent committee under DHSC
Reimbursement body / payer
NHS England / ICBs (Integrated Care Boards)
Reimbursement route
NHS Drug Tariff Part XV - GP or paediatrician prescription
Tender / procurement mechanism
No formal national tender; local ICB formularies create de facto preferred product lists
Local formulary / restriction layer
ICB / IMOC prescribing guidelines (e.g. SEL IMOC; Kent & Medway IMOC) restrict first-line use
Step-up protocol (eHF -> AAF)
Yes - eHF first-line for mild-moderate CMA; AAF (e.g. Neocate) requires step-up or dietitian justification
Key notes / caveats
ACBS listing is indication-specific. Local ICB guidelines are increasingly cost-driven. Neocate Junior requires written dietitian request and cannot be initiated in primary care.
SKUs in scope (12)
Aptamil · 4APT-PEP1-800APT-PEP2-800APT-PEPJR-450APT-SYN-400
Neocate · 5NEO-LCP-400NEO-SYN-400NEO-JR-400NEO-ACT-SCHNEO-SPN-100
Cow & Gate · 3CG-PEP1-800CG-PEP2-800CG-NPH-800
Confidence: High - well documented
Comparison matrix
| Market | Class | Approval body | Payer | Route | Tender mechanism | Step-up | Time | Confidence |
|---|---|---|---|---|---|---|---|---|
| 🇬🇧 UK | FSMP | ACBS (Advisory Committee on Borderline Substances) | NHS England / ICBs (Integrated Care Boards) | Borderline substance | No formal national tender; local ICB formularies create de facto preferred product lists | Yes | 14 mo | ● High |
| 🇩🇪 DE | FSMP | BfR (Bundesinstitut fur Risikobewertung) | GKV (Gesetzliche Krankenversicherung) - statutory health insurance funds | Insurer-led | GKV rebate contracting (Arzneimittelrabattvertrage) - functionally similar to tender; individual Krankenkassen may have preferred supplier agreements | Yes | 12 mo | ● Moderate |
| 🇫🇷 FR | FSMP | HAS (Haute Autorite de Sante) may issue clinical guidance; CNAM manages reimbursement lists | CNAM / Assurance Maladie | National list | Partial - CEPS negotiates pricing; no open tender per se but price is controlled nationally | Yes | 11 mo | ● Moderate |
| 🇮🇹 IT | FSMP | Ministero della Salute manages FSMP register; AIFA handles medicines only | Regional health authorities (ASL / SSN) | Regional tender | Yes - regional procurement varies significantly; some regions tender or restrict to approved lists | Yes | 9 mo | ● Moderate |
| 🇪🇸 ES | FSMP | AEMPS for registration; Ministry of Health / CIPM for medicines pricing | SNS (Sistema Nacional de Salud) | Regional tender | Yes - CCAA can tender or restrict products locally; significant inter-regional variation in which products are funded | Yes | 10 mo | ● Moderate |
| 🇳🇱 NL | FSMP | ZIN (Zorginstituut Nederland) for benefit package decisions; NZa for pricing oversight | Private health insurers (Achmea / VGZ / CZ / Menzis cover ~85%) | Insurer-led | Yes - insurer-led preferred supplier contracting; functionally similar to tender; ZN CieBAG plays advisory role | Yes | 8 mo | ● Moderate-High |
| 🇧🇪 BE | FSMP | NIHDI / RIZIV-INAMI manages compulsory health insurance product listing | NIHDI / RIZIV-INAMI | Reimbursement | No formal national tender for FSMPs as far as confirmed - verify | Yes | 9 mo | ● Low-Moderate |
| 🇵🇱 PL | FSMP | URPL for registration; Ministry of Health (MZ) and NFZ for reimbursement listing | NFZ (Narodowy Fundusz Zdrowia) - single national payer | Tender | NFZ procurement processes apply - functionally tender-like for listed products | Yes | 7 mo | ● Low-Moderate |
| 🇸🇪 SE | FSMP | TLV handles pharmaceutical reimbursement; FSMPs handled via separate regional route | 21 regional county councils (regioner) - each region procures independently | Regional tender | Yes - strong regional procurement; individual regions tender for preferred FSMP products; significant inter-regional variation | Yes | 10 mo | ● Moderate |
Need a definition? See the Glossary tab - or hover any pill, KPI or column header for a quick inline tooltip.